Jiangsu Lianhuan Pharmaceutical Stock Forum

The company's earnings power may be weaker than reported due to unusual items. Without these items and business growth, next year's profit could be weaker.

Jiangsu Lianhuan Pharmaceutical's low P/E ratio may reflect investor expectations of underperformance compared to the broader market. The company's recent medium-term earnings trajectory is less attractive, leading investors to pay less for the stock, expecting limited growth rates to continue.